NDC-1308
Multiple Sclerosis / Neurodegenerative Disease
PreclinicalActive
Key Facts
About Endece
Endece is a neuroscience-focused biotech developing NDC-1308, a novel small molecule with a dual mechanism of action targeting remyelination and demyelination for neurodegenerative diseases like multiple sclerosis (MS). The company possesses a proprietary compound library with over 100 issued patents and is led by its founder, Dr. James Yarger, an experienced scientist and executive. Currently in the preclinical stage, Endece's strategy hinges on advancing NDC-1308 into clinical trials to address a significant unmet need in neurodegenerative diseases where current therapies primarily manage symptoms rather than repair damage.
View full company profile